• Coherus BioSciences Inc CHRS.OQ reported a quarterly adjusted loss of 1 cent​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -27 cents. The mean expectation of nine analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -28 cents to 2 cents per share.

• Revenue fell 5.1% to $70.77 million from a year ago; analysts expected $59.23 million.

• Coherus BioSciences Inc's reported EPS for the quarter was a loss of 9 cents​.

• The company reported a quarterly loss of $10.75 million.

• Coherus BioSciences Inc shares had fallen by 29.7% this quarter and lost 78.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 7.9% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Coherus BioSciences Inc is 8.00

This summary was machine generated from LSEG data November 7 at 04:26 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)